Sara A. Courtneidge, Ph.D.[La Jolla]
Previous studies by our group and others have demonstrated that we might be able to target invadopodia to prevent cancer cell invasiveness.
Dr. Courtneidge studies Src and its substrates and their roles in invadopodia/podosome formation, and cancer progression.
Dr. Courtneidge received her Ph.D. from the National Institute for Medical Research.
The SRC substrate Tks5, podosomes (invadopodia), and cancer cell invasion.
Courtneidge SA, Azucena EF, Pass I, Seals DF, Tesfay L
Cold Spring Harb Symp Quant Biol. 2005;70:167-71
The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells.
Seals DF, Azucena EF, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH, Courtneidge SA
Cancer Cell. 2005 Feb;7(2):155-65
Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts.
Bromann PA, Korkaya H, Webb CP, Miller J, Calvin TL, Courtneidge SA
J Biol Chem. 2005 Mar 18;280(11):10253-63
The interplay between Src family kinases and receptor tyrosine kinases.
Bromann PA, Korkaya H, Courtneidge SA
Oncogene. 2004 Oct 18;23(48):7957-68
Cancer: Escape from inhibition.
Nature. 2003 Apr 24;422(6934):827-8
The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells.
Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM, Courtneidge SA
J Biol Chem. 2003 May 9;278(19):16844-51
Isolation of novel Src substrates.
Biochem Soc Trans. 2003 Feb;31(Pt 1):25-8
The ADAMs family of metalloproteases: multidomain proteins with multiple functions.
Seals DF, Courtneidge SA
Genes Dev. 2003 Jan 1;17(1):7-30
Role of Src in signal transduction pathways. The Jubilee Lecture.
Biochem Soc Trans. 2002 Apr;30(2):11-7
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7319-24
View All Publications
Invadopodia Are Required for Cancer Cell Extravasation and Are a Therapeutic Target for Metastasis.
Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA, Postenka CO, Turley EA, Courtneidge SA, Chambers AF, Lewis JD
Cell Rep. 2014 Aug 27;
Sara A. Courtneidge's Research Focus
Cancer, Brain Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Skin Cancer and Melanoma, Inherited Disorders
Watch Dr. Courtneidge describe her research
Dr. Courtneidge’s laboratory has studied the Src family of protein tyrosine kinases for a number of years. Src was the first oncogene to be discovered, and the first protein tyrosine kinase, and dissecting the mechanisms of Src transformation, regulation, substrate selection and function has proven to be a powerful research paradigm to understand tumorigenesis. In addition, since Src is frequently up-regulated and hyperactivated in human cancers, particularly of the breast and colon, such research is of direct relevance to human disease. Current research in the laboratory focuses on three main areas. The first involves defining how Src and its substrates, Tks4 and Tks5, drive the formation of podosomes and invadopodia, which are protrusive membrane structures of normal and cancer cells respectively that coordinate migration with extracellular matrix degradation. Since invadopodia are found in metastatic human cancer cells, the second focus is to identify and validate molecular targets in invadopodia, in order to define novel therapeutic points of intervention for the treatment of metastatic disease. The third research area involves defining in molecular detail the role of the Tks adaptor proteins during development, using both zebrafish and mice as model organisms.
About Sara A. Courtneidge
Sara A. Courtneidge, Ph.D. is Professor and Director of the Tumor Microenvironment Program, and Director of Academic Affairs at Sanford-Burnham Medical Research Institute in La Jolla, California. Dr. Courtneidge was born in the UK, and received her undergraduate degree from the University of Leeds and her Ph.D. from the National Institute for Medical Research. Following postdoctoral study at the University of California, San Francisco, and an independent position at the National Institute for Medical Research, she joined the European Molecular Biology Laboratory in 1985, where she rose to the position of Senior Scientist. Changing course in 1994, Dr. Courtneidge joined SUGEN Inc. as Vice President of Research, where she guided novel kinase discovery and validation efforts in oncology. From 2001-2005 she was Distinguished Scientific Investigator at the Van Andel Research Institute in Grand Rapids, Michigan. Dr. Courtneidge joined Sanford-Burnham Medical Research Institute in May 2005.
Dr. Courtneidge received her undergraduate degree from the University of Leeds and her Ph.D. from the National Institute for Medical Research. She completed postdoctoral studies at the University of California, San Francisco.
• Adjunct Professor, Department of Pharmacology, University of California, San Diego
Honors and Recognition
• Elected member of the European Molecular Biology Organization (1990)
• The Jubilee Lecture and Harden Medal of the British Biochemical Society (2001)
• The Feodor Lynen Lecture and Lynen Medal, Nature Biotechnology Winter Symposium (2005)
• Doctor of Science (honoris causa), The University of Leeds, UK (2006)
MEMBERSHIP IN PROFESSIONAL SOCIETIES
• American Association for Cancer Research
• European Molecular Biology Organization
• American Society for Biochemistry and Molecular Biology
American Society of Cell Biology
ADVISORY AND REVIEW BOARD PARTICIPATION
• Basic Mechanisms of Cancer Therapeutics Study Section (2007-2011) (Chair 2009-2011)
• Scientific Review Board, Howard Hughes Medical Institute (2008- )
• American Association for Cancer Research
Strategic Planning Meeting, Think Tanks and various Prize Selection Committees (2002- ), Board of Directors (2005-2008), Nominating Committee (2009-2010), Finance and Audit Committee (2010-2013)
• Children’s Tumor Foundation Research Advisory Board (1998- )
• Board of Directors of the Foundation for Advanced Cancer Studies (2000- )
• Scientific Advisory Board, Abramson Family Cancer Research Institute (2006-2009)
• Scientific Advisory Committee, Tobacco-related Disease Research Program, CA (2008- )
• Scientific Advisory Board, The Forbeck Foundation (2009- )
• Scientific Advisory Board, Crown Biosciences (2008- )
EDITORIAL BOARD MEMBERSHIP
• Genes and Development (1992- )
• Cancer Cell (2002- )
• Pharmacology and Therapeutics (2010- )
• Cancer Discovery (2011- )
• Co-organizer, Oncogene meeting (1995)
• Co-organizer, Cold Spring Harbor Conference on Protein Phosphorylation, Cell Signaling and Disease (1999, 2001, 2003, 2005, 2007, 2009)
• Co-organizer, Keystone Symposium on Cancer Intervention (2001)
• Program Chair, American Association for Cancer Research Annual Meeting (2003)
• Co-organizer, Keystone Symposium on Molecular Targets for Cancer Therapy (2005)
• Co-organizer, AACR special conference, Drugging the Cancer Genome (2006)
• Co-organizer, Salk Institute Conference on Protein Phosphorylation and Cell Signaling (2006, 2008, 2010)
• Co-organizer, Keystone Symposium on Molecular Targets in Cancer (2007)
• Program Chair, AACR-NCI-EORTC Molecular Targets Conference (2007)
• Program Executive Committee Member, AACR-NCI-EORTC Molecular Targets Conference (2009)
• Program Committee Member, AACR Annual Meeting (2010)
• Program Chair, Molecular Therapeutics of Cancer Conference (2011)